Proficio Capital Partners LLC Makes New $1.10 Million Investment in Abbott Laboratories $ABT

Proficio Capital Partners LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 12,158 shares of the healthcare product maker’s stock, valued at approximately $1,103,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Freemont Management S.A. increased its holdings in Abbott Laboratories by 197.2% during the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares during the last quarter. Thrivent Financial for Lutherans grew its position in shares of Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after acquiring an additional 48,286 shares during the period. Aureus Asset Management LLC raised its holdings in shares of Abbott Laboratories by 25.0% in the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after purchasing an additional 66,422 shares during the period. North Dakota State Investment Board purchased a new stake in Abbott Laboratories in the fourth quarter worth $7,439,000. Finally, Thompson Investment Management Inc. grew its stake in shares of Abbott Laboratories by 786.0% during the 2nd quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock worth $1,276,000 after acquiring an additional 12,474 shares during the period. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Bank of America cut their price target on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. BTIG Research lifted their price target on shares of Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. The Goldman Sachs Group reduced their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $108.29 on Friday. The firm has a market cap of $187.38 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company’s fifty day simple moving average is $104.43 and its two-hundred day simple moving average is $100.12. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period last year, the firm earned $1.26 earnings per share. Abbott Laboratories’s quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.